Elizabet Shvets

Elizabet Shvets supports clients in market access, product commercialization, reimbursement strategy, and policy impact assessment.

With a particular interest in novel therapies, Elizabet supports clients by providing guidance on the unique operational, financial, and distribution considerations for cell and gene therapies, including value-based care implementation. She also applies her research and data analytics experience to support clients with gross-to-net modeling, site of care analysis, and channel strategy assessment.

Prior to joining Avalere, Elizabet worked as a research assistant at the Hunter College Economics Department where she conducted empirical and descriptive research to support health economics research, including the impact of vertical integration on medical malpractice. Additionally, she completed an internship in the Policy and Research Department at PhRMA where she analyzed the drug policy landscape and conducted research to support advocacy efforts around cell and gene therapies and the 340B program.

Elizabet is a PhD Candidate in health policy at the George Washington University. She also received a BA and MA in economics from Hunter College and minored in mathematics.

Authored Content

The intersection of upcoming changes to drug pricing metrics will require new methods of calculating and reporting government pricing with implications for net pricing and contracting strategies.

Manufacturers currently in the developmental phase for drug assets targeting rare or orphan diseases should assess the commercialization implications when bringing novel therapies to market and how they may differ from the standard pharmaceutical supply chain and economics.